Designing inhibitors of cyclin-dependent kinases

Annual Review of Pharmacology and Toxicology

Volumn 42, Issue , 2002, Pages 325-348

  Hardcastle, Ian R ^a   Golding, Bernard T ^a   Griffin, Roger J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cancer chemotherapy; Cell cycle; Experimental therapeutics

Indexed keywords

2,6 DIAMINO 4 CYCLOHEXYLMETHOXY 5 NITROSOPYRIMIDINE; 6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE; 6 O CYCLOHEXYLMETHYLGUANINE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BUTYROLACTONE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; DESCHLOROFLAVOPIRIDOL; FLAVOPIRIDOL; GEFITINIB; INDIRUBIN; KENPAULLONE; PAULLONE; PROTEIN P16; PROTEIN P21; PROTEIN P53; PURVANALOL A; PURVANALOL B; QUINAZOLINE DERIVATIVE; ROHITUKINE; ROSCOVITINE; STAUROSPORINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL CYCLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SELECTIVITY; HUMAN; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; CYCLIN-DEPENDENT KINASES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036181669     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.42.090601.125940     Document Type: Review

References (32)

1. Active and inactive protein kinases: Structural basis for regulation
2. Principles of CDK regulation
3. Mechanisms of cyclin-dependent kinase regulation: Structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors
4. Crystal structure of cyclin dependent kinase 2
5. Mechanism of cdk activation revealed by the structure of cyclin A-cdk2 complexes
6. Structural basis of cyclin-dependent kinase activation by phosphorylation
7. High-resolution crystal structures of human cyclin -dependent kinase 2 with and without ATP: Bound waters and natural ligand as guides for inhibitor design
8. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase
9. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
10. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumour therapy
11. Discovery and initial characterisation of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases
12. Indirubin, the active costituent of a Chinese antileukemia medicine, inhibits cyclin-dependent kinases
13. Characterisation of novel inhibitors of cyclin-dependent kinases
14. Pyrido [2,3-d]pyrimidin-7-one inhibitors of cyclin dependent kinases
15. Inhibition of cyclin-dependent kinases by purine analogues
16. Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds
17. Biochemical and cellular effects of roscovitive, a potent selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5
18. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm
19. Inhibition of cyclin-dependent kinases by purine analogues
20. A structure-based library approach to kinase inhibitors
21. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
22. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors
23. 2,6,9-Trisubstituted purines: Optimisation towards highly potent and selective CDK1 inhibitors
24. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases
25. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex
26. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
27. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors
28. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase
29. Quinazolines as cyclin dependent kinase inhibitors
30. Inhibition of cyclin -dependent kinases, GSK-3β, and CK1 by hymenialdisine, a marine sponge constituent
31. Cyclin-dependent kinase inhibitors: Useful targets in cell cycle regulation